Citations (122)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Rui Zhang, Samantha D Clark, Beibei Guo, Tianyi Zhang, Duane Jeansonne, Samithamby J Jeyaseelan, Joseph Francis & Weishan Huang. (2023) Challenges in the combination of radiotherapy and immunotherapy for breast cancer. Expert Review of Anticancer Therapy 23:4, pages 375-383.
Read now
Read now
Bei Wang, Limiao Zhao & Dandan Chen. (2022) Coactosin-Like Protein in Breast Carcinoma: Friend or Foe?. Journal of Inflammation Research 15, pages 4013-4025.
Read now
Read now
Yiqi Fan & Shuai He. (2022) The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer. Cancer Management and Research 14, pages 1-17.
Read now
Read now
Zhi Bing Liu, Luyan Zhang, Jia Bian & Jinbo Jian. (2020) Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer. OncoTargets and Therapy 13, pages 2657-2666.
Read now
Read now
Steven J Greco. (2019) Breast cancer risk in a rapidly aging population: advances and approaches to study the aging tissue microenvironment. Breast Cancer: Targets and Therapy 11, pages 111-113.
Read now
Read now
Nehad M Ayoub, Kamal M Al-Shami & Rami J Yaghan. (2019) Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. Breast Cancer: Targets and Therapy 11, pages 53-69.
Read now
Read now
Susanna Gallo, Dario Sangiolo, Fabrizio Carnevale Schianca, Massimo Aglietta & Filippo Montemurro. (2017) Treating breast cancer with cell-based approaches: an overview. Expert Opinion on Biological Therapy 17:10, pages 1255-1264.
Read now
Read now
Mathilde Guerin, Anthony Gonçalves, Yves Toiron, Emilie Baudelet, Stéphane Audebert, Jean-Baptiste Boyer, Jean-Paul Borg & Luc Camoin. (2017) How may targeted proteomics complement genomic data in breast cancer?. Expert Review of Proteomics 14:1, pages 43-54.
Read now
Read now
Andrea Ravelli, James M Reuben, Francesco Lanza, Simone Anfossi, Maria Rosa Cappelletti, Laura Zanotti, Angela Gobbi, Manuela Milani, Daniele Spada, Paolo Pedrazzoli, Massimo Martino, Alberto Bottini & Daniele Generali. (2015) Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity. Expert Review of Anticancer Therapy 15:6, pages 689-702.
Read now
Read now
Andrea Milani, Dario Sangiolo, Massimo Aglietta & Giorgio Valabrega. (2014) Recent advances in the development of breast cancer vaccines. Breast Cancer: Targets and Therapy 6, pages 159-168.
Read now
Read now
Articles from other publishers (112)
Jian Xu, Chen Gan, Sheng Yu, Senbang Yao, Wen Li & Huaidong Cheng. (2023) Analysis of Immune Resistance Mechanisms in TNBC: Dual Effects Inside and Outside the Tumor. Clinical Breast Cancer.
Crossref
Crossref
Natalia Sauer, Igor Matkowski, Grażyna Bodalska, Marek Murawski, Piotr Dzięgiel & Jacek Calik. (2023) Prognostic Role of Prolactin-Induced Protein (PIP) in Breast Cancer. Cells 12:18, pages 2252.
Crossref
Crossref
Wei Zhang, Yujing He, Yuning Tang, Wei Dai, Yuexiu Si, Feiyan Mao, Jiaxuan Xu, Chiyuan Yu & Xing Sun. (2023) A meta-analysis of application of PD-1/PD-L1 inhibitor-based immunotherapy in unresectable locally advanced triple-negative breast cancer. Immunotherapy 15:13, pages 1073-1088.
Crossref
Crossref
Sulieman Ibraheem Shelash Al-Hawary, Ebraheem Abdu Musad Saleh, Nodirjon Akhmetovich Mamajanov, Gilmanova Nataliya Sergeevna, Hashem O. Alsaab, Adel Alghamdi, Shakeel Ahmed Ansari, Ahmed Hussien Radie Alawady, Ali Hashiem Alsaalamy & Ahmed Jaber Ibrahim. (2023) Breast cancer vaccines; A comprehensive and updated review. Pathology - Research and Practice, pages 154735.
Crossref
Crossref
Mengjie Liu, Chaofan Li, Jingkun Qu, Shiyu Sun, Zitong Zhao, Weiwei Wang, Wei Lv, Yu Zhang, Yifan Cai, Fang Zhao, Fei Wu, Shuqun Zhang & Xixi Zhao. (2023) Baicalein enhances immune response in TNBC by inhibiting leptin expression of adipocytes. Cancer Science.
Crossref
Crossref
Hengli Zhou, Junyu Ke, Changhua Liu, Menglu Zhu, Bijuan Xiao, Qi Wang, Rui Hou, Yueer Zheng, Yongqiang Wu, Xingting Zhou, Xinlin Chen & Huafeng Pan. (2023) Potential prognostic and immunotherapeutic value of calponin 1: A pan-cancer analysis. Frontiers in Pharmacology 14.
Crossref
Crossref
Tingting Yang, Lihua Kang, Dan Li & Yanqiu Song. (2023) Immunotherapy for HER-2 positive breast cancer. Frontiers in Oncology 13.
Crossref
Crossref
Dara Bakar & Raman Mehrzad. 2023. The Link Between Obesity and Cancer. The Link Between Obesity and Cancer
83
113
.
Sara Kamali Zonouzi, Sepideh Razi & Nima Rezaei. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
28
.
Luka Peric, Sonja Vukadin, Ana Petrovic, Lucija Kuna, Nora Puseljic, Renata Sikora, Karla Rozac, Aleksandar Vcev & Martina Smolic. (2022) Glycosylation Alterations in Cancer Cells, Prognostic Value of Glycan Biomarkers and Their Potential as Novel Therapeutic Targets in Breast Cancer. Biomedicines 10:12, pages 3265.
Crossref
Crossref
Rui He, Xing Yuan, Zeran Chen & Yongfeng Zheng. (2022) Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking. International Immunopharmacology 113, pages 109444.
Crossref
Crossref
Akindele Olagunju, Tia Forsman & Robert C. Ward. (2022) An update on the use of cryoablation and immunotherapy for breast cancer. Frontiers in Immunology 13.
Crossref
Crossref
Sedighe Forouhari, Zahra Beygi, Zahra Mansoori, Sara Hajsharifi, Fatemeh Heshmatnia & Seyed Mohammad Gheibihayat. (2021) Liposomes: Ideal drug delivery systems in breast cancer. Biotechnology and Applied Biochemistry 69:5, pages 1867-1884.
Crossref
Crossref
Ruo Qi Li, Wei Wang, Lei Yan, Li Ying Song, Xin Guan, Wei Zhang & Jing Lian. (2022) Identification of tumor antigens and immune subtypes in breast cancer for mRNA vaccine development. Frontiers in Oncology 12.
Crossref
Crossref
Jia Li, Fei Wu, Chaofan Li, Shiyu Sun, Cong Feng, Huizi Wu, Xi Chen, Weiwei Wang, Yu Zhang, Mengji Liu, Xuan Liu, Yifan Cai, Yiwei Jia, Hao Qiao, Yinbin Zhang & Shuqun Zhang. (2022) The cuproptosis-related signature predicts prognosis and indicates immune microenvironment in breast cancer. Frontiers in Genetics 13.
Crossref
Crossref
Qiang Tang, Shurui Wang, Ziyang Di, Huimin Li, Kailiang Xu, Xin Hu & Maojun Di. (2022) Identification and validation of a prognostic risk model based on caveolin family genes for breast cancer. Frontiers in Cell and Developmental Biology 10.
Crossref
Crossref
Zaria Malindi, Stefan Barth & Heidi Abrahamse. (2022) The Potential of Antibody Technology and Silver Nanoparticles for Enhancing Photodynamic Therapy for Melanoma. Biomedicines 10:9, pages 2158.
Crossref
Crossref
Huamei Li, Hongjia Liu, Qiongyu Hao, Xianglin Liu, Yongzhong Yao & Meng Cao. (2022) Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer. Frontiers in Immunology 13.
Crossref
Crossref
María Lilia Nicolás-Morales, Arianna Luisa-Sanjuan, Mayralina Gutiérrez-Torres, Amalia Vences-Velázquez, Carlos Ortuño-Pineda, Mónica Espinoza-Rojo, Napoleón Navarro-Tito & Karen Cortés-Sarabia. (2022) Peptide-Based Vaccines in Clinical Phases and New Potential Therapeutic Targets as a New Approach for Breast Cancer: A Review. Vaccines 10:8, pages 1249.
Crossref
Crossref
Yan Li, Xiang Zhou & Hongyuan Cao. (2022) Statistical analysis of spatially resolved transcriptomic data by incorporating multiomics auxiliary information. Genetics 221:4.
Crossref
Crossref
Alexander S. Franzén, Martin J. Raftery & Gabriele Pecher. (2022) Implications for Immunotherapy of Breast Cancer by Understanding the Microenvironment of a Solid Tumor. Cancers 14:13, pages 3178.
Crossref
Crossref
Sara Hadjigol, Bansari A. Shah & Neil M. O’Brien-Simpson. (2022) The ‘Danse Macabre’—Neutrophils the Interactive Partner Affecting Oral Cancer Outcomes. Frontiers in Immunology 13.
Crossref
Crossref
RuYan Li, QingHua Zheng, QiuPing Deng, Yi Wang, HaoDing Yang, Jian Shen, YingHui Liu & JiaHong Zhou. (2022) A Dual Functional Drug Delivery System that Combines Photothermal Therapy and Immunotherapy to Treat Tumors. Molecular Pharmaceutics 19:5, pages 1449-1457.
Crossref
Crossref
Jiayue Luo & Jianguo Lai. (2022) Pyroptosis‐related molecular classification and immune microenvironment infiltration in breast cancer: A novel therapeutic target. Journal of Cellular and Molecular Medicine 26:8, pages 2259-2272.
Crossref
Crossref
Alba Navarro-Ocón, Jose L. Blaya-Cánovas, Araceli López-Tejada, Isabel Blancas, Rosario M. Sánchez-Martín, María J. Garrido, Carmen Griñán-Lisón, Jesús Calahorra, Francisca E. Cara, Francisco Ruiz-Cabello, Juan A. Marchal, Natalia Aptsiauri & Sergio Granados-Principal. (2022) Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer. Pharmaceutics 14:3, pages 505.
Crossref
Crossref
Xiaoqiang Yin, Tongchui Wu, Yadong Lan & Wulin Yang. (2022) Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma. Bioscience Reports 42:2.
Crossref
Crossref
Tian Tian, JinMing Fu, DaPeng Li, YuPeng Liu, HongRu Sun, Xuan Wang, XianYu Zhang, Ding Zhang, Ting Zheng, Yashuang Zhao & Da Pang. (2022) Methylation of Immune-Related Genes in Peripheral Blood Leukocytes and Breast Cancer. Frontiers in Oncology 12.
Crossref
Crossref
Si-Yuan Zhu & Ke-Da Yu. (2022) Breast Cancer Vaccines: Disappointing or Promising?. Frontiers in Immunology 13.
Crossref
Crossref
I. V. Vasilevskaya & O. E. Molchanov. (2022) IMMUNOLOGICAL FEATURES OF BREAST CANCER. Laboratornaya i klinicheskaya meditsina. Farmatsiya:5, pages 27-36.
Crossref
Crossref
Tahir Bashir Dar, Adil Rafiq Bhat, Fleury Augustin Nsole Biteghe, Ab Raouf Bhat & Zaria Malindi. 2022. Fundamentals and Advances in Medical Biotechnology. Fundamentals and Advances in Medical Biotechnology
325
361
.
Nadeem Bilani, Elizabeth Blessing Elimimian, Leah Elson, Hong Liang & Zeina Nahleh. 2021. Global Women's Health. Global Women's Health.
Rodrigo Kern & Carolina Panis. (2021) CTLA-4 Expression and Its Clinical Significance in Breast Cancer. Archivum Immunologiae et Therapiae Experimentalis 69:1.
Crossref
Crossref
Minhong Shen, Heath A. Smith, Yong Wei, Yi-Zhou Jiang, Sheng Zhao, Nicole Wang, Michelle Rowicki, Yong Tang, Xiang Hang, Songyang Wu, Liling Wan, Zhi-Ming Shao & Yibin Kang. (2021) Pharmacological disruption of the MTDH–SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer. Nature Cancer 3:1, pages 60-74.
Crossref
Crossref
He Ren, Shuliang Li, Xin Liu, Wanjing Li, Jianlei Hao & Na Zhao. (2021) Multi-omics analysis of the expression and prognostic value of the butyrophilins in breast cancer. Journal of Leukocyte Biology 110:6, pages 1181-1195.
Crossref
Crossref
Zhiquan Xu, Ling Xiang, Rong Wang, Yongfu Xiong, He Zhou, Haitao Gu, Jijian Wang & Linglong Peng. (2021) Bioinformatic Analysis of Immune Significance of RYR2 Mutation in Breast Cancer. BioMed Research International 2021, pages 1-12.
Crossref
Crossref
Fatima-Zohra Khadri, Marianne Samir Makboul Issac & Louis Arthur Gaboury. (2021) Impact of Epithelial–Mesenchymal Transition on the Immune Landscape in Breast Cancer. Cancers 13:20, pages 5099.
Crossref
Crossref
Thaise Gonçalves Araújo, Sara Teixeira Soares Mota, Helen Soares Valença Ferreira, Matheus Alves Ribeiro, Luiz Ricardo Goulart & Lara Vecchi. (2021) Annexin A1 as a Regulator of Immune Response in Cancer. Cells 10:9, pages 2245.
Crossref
Crossref
Yuan-ke Liang, Ze-kun- Deng, Mu-tong Chen, Si-qi Qiu, Ying-sheng Xiao, Yu-zhu Qi, Qin Xie, Zheng-hao Wang, Shi-cheng Jia, De Zeng & Hao-yu Lin. (2021) CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer. Frontiers in Oncology 11.
Crossref
Crossref
Qianhui Xu, Shaohuai Chen, Yuanbo Hu & Wen Huang. (2021) Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer. Frontiers in Immunology 12.
Crossref
Crossref
Jensen N. Amens, Gökhan Bahçecioglu & Pinar Zorlutuna. (2021) Immune System Effects on Breast Cancer. Cellular and Molecular Bioengineering 14:4, pages 279-292.
Crossref
Crossref
Hemavathy Subramaiam, Wan-Loy Chu, Ammu Kutty Radhakrishnan, Srikumar Chakravarthi, Kanga Rani Selvaduray & Yih-Yih Kok. (2021) Evaluating Anticancer and Immunomodulatory Effects of Spirulina (Arthrospira) platensis and Gamma-Tocotrienol Supplementation in a Syngeneic Mouse Model of Breast Cancer. Nutrients 13:7, pages 2320.
Crossref
Crossref
Bader Alshehri. (2021) Immunotherapy: New insights in breast cancer treatment. Human Antibodies 29:3, pages 193-202.
Crossref
Crossref
Fatima Noor, Ayesha Noor, Ali Raza Ishaq, Iqra Farzeen, Muhammad Hamzah Saleem, Kanwal Ghaffar, Muhammad Farhan Aslam, Sidra Aslam & Jen-Tsung Chen. (2021) Recent Advances in Diagnostic and Therapeutic Approaches for Breast Cancer: A Comprehensive Review. Current Pharmaceutical Design 27:20, pages 2344-2365.
Crossref
Crossref
Julia Beatrice de Araújo, Vanessa Vitória Kerkhoff, Sarah Franco Vieira de Oliveira Maciel & Débora Tavares de Resende e Silva. (2021) Targeting the purinergic pathway in breast cancer and its therapeutic applications. Purinergic Signalling 17:2, pages 179-200.
Crossref
Crossref
Arielle L. Heeke & Antoinette R. Tan. (2021) Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. Cancer and Metastasis Reviews 40:2, pages 537-547.
Crossref
Crossref
Tyrillshall S. T. Damiana & Simone U. Dalm. (2021) Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer. Pharmaceutics 13:5, pages 674.
Crossref
Crossref
MOTAWA E. EL-HOUSEINI, MOSTAFA S. ARAFAT, AHMED M. EL-HUSSEINY, ISLAM M. KASEM, MAHMOUD M. KAMEL, AHMED H. EL-HABASHY, MEDHAT M. KHAFAGY, ENAS M. RADWAN, MAHA H. HELAL & MONA S. ABDELLATEIF. (2021) Biological and molecular studies on specific immune cells treated with checkpoint inhibitors for the thera-personal approach of breast cancer patients (ex-vivo study). Oncology Research 29:5, pages 319-329.
Crossref
Crossref
. (2020) Metastasis: A Bane of Breast Cancer Therapy. European Medical Journal.
Crossref
Crossref
Michael S. Toss, Asima Abidi, Dorothea Lesche, Chitra Joseph, Sakshi Mahale, Hugo Saunders, Tanjina Kader, Islam M. Miligy, Andrew R. Green, Kylie L. Gorringe & Emad A. Rakha. (2020) The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. British Journal of Cancer 122:10, pages 1496-1506.
Crossref
Crossref
Farzaneh Afzali, Zarrin Minuchehr, Samira Jahangiri & Mohammad Mehdi Ranjbar. (2020) Immunopeptidome screening to design An immunogenic construct against PRAME positive breast cancer; An in silico study. Computational Biology and Chemistry 85, pages 107231.
Crossref
Crossref
Paola Ciciola, Priscilla Cascetta, Cataldo Bianco, Luigi Formisano & Roberto Bianco. (2020) Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. Journal of Clinical Medicine 9:3, pages 675.
Crossref
Crossref
Peiling Xie, Yuying Ma, Shibo Yu, Rui An, Jianjun He & Huimin Zhang. (2020) Development of an Immune-Related Prognostic Signature in Breast Cancer. Frontiers in Genetics 10.
Crossref
Crossref
Nahla M. Badr, Fedor Berditchevski & Abeer M. Shaaban. (2020) The Immune Microenvironment in Breast Carcinoma: Predictive and Prognostic Role in the Neoadjuvant Setting. Pathobiology 87:2, pages 61-74.
Crossref
Crossref
Qinglian Zhai, Jiawen Fan, Qiulian Lin, Xia Liu, Jinting Li, Ruoxi Hong & Shusen Wang. (2019) Tumor stromal type is associated with stromal PD-L1 expression and predicts outcomes in breast cancer. PLOS ONE 14:10, pages e0223325.
Crossref
Crossref
Tower, Ruppert & Britt. (2019) The Immune Microenvironment of Breast Cancer Progression. Cancers 11:9, pages 1375.
Crossref
Crossref
Asis Bala & Shravani Sripathi Panditharadyula. (2019) Role of Nuclear Factor Erythroid 2-Related Factor 2 (NRF-2) Mediated Antioxidant Response on the Synergistic Antitumor Effect of L-Arginine and 5-Fluro Uracil (5FU) in Breast Adenocarcinoma. Current Pharmaceutical Design 25:14, pages 1643-1652.
Crossref
Crossref
M. Heval Ozgen & Stuart Blume. (2019) The continuing search for an addiction vaccine. Vaccine 37:36, pages 5485-5490.
Crossref
Crossref
Chidalu Edechi, Nnamdi Ikeogu, Jude Uzonna & Yvonne Myal. (2019) Regulation of Immunity in Breast Cancer. Cancers 11:8, pages 1080.
Crossref
Crossref
Andrea Nicolini, Vivian Barak, Piermario Biava, Paola Ferrari, Giuseppe Rossi & Angelo Carpi. (2019) The Use of Immunotherapy to Treat Metastatic Breast Cancer. Current Medicinal Chemistry 26:6, pages 941-962.
Crossref
Crossref
Qianglan Lu, Sun Qi, Peishan Li, Lifang Yang, Shan Yang, Yidan Wang, Yu Cheng, Yilin Song, Siyu Wang, Fengping Tan & Nan Li. (2019) Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy. Journal of Materials Chemistry B 7:15, pages 2499-2511.
Crossref
Crossref
Natascha Stergiou, Nikola Gaidzik, Anne-Sophie Heimes, Sarah Dietzen, Pol Besenius, Jörg Jäkel, Walburgis Brenner, Marcus Schmidt, Horst Kunz & Edgar Schmitt. (2019) Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid. Cancer Immunology Research 7:1, pages 113-122.
Crossref
Crossref
Soley Bayraktar. 2019. Breast Disease. Breast Disease
541
552
.
Varun Sasidharan Nair, Haytham El Salhat, Rowaida Z. Taha, Anne John, Bassam R. Ali & Eyad Elkord. (2018) DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clinical Epigenetics 10:1.
Crossref
Crossref
Joanne K. Gardner, Connie Jackaman, Cyril D. S. Mamotte & Delia J. Nelson. (2018) The Regulatory Status Adopted by Lymph Node Dendritic Cells and T Cells During Healthy Aging Is Maintained During Cancer and May Contribute to Reduced Responses to Immunotherapy. Frontiers in Medicine 5.
Crossref
Crossref
Estefanía Paula Juliá, Analía Amante, María Betina Pampena, José Mordoh & Estrella Mariel Levy. (2018) Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells. Frontiers in Immunology 9.
Crossref
Crossref
Maryann J. Kwa & Sylvia Adams. (2018) Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. Cancer 124:10, pages 2086-2103.
Crossref
Crossref
Ari Kassardjian, Peter I. Shintaku & Neda A. Moatamed. (2018) Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas. PLOS ONE 13:4, pages e0195958.
Crossref
Crossref
Olivia Ihedioha, Anne A. Blanchard, Jyoti Balhara, Ifeoma Okwor, Ping Jia, Jude Uzonna & Yvonne Myal. (2018) The human breast cancer-associated protein, the prolactin-inducible protein (PIP), regulates intracellular signaling events and cytokine production by macrophages. Immunologic Research 66:2, pages 245-254.
Crossref
Crossref
Dmitri V. Rozanov, Nikita D. Rozanov, Kami E. Chiotti, Ashok Reddy, Phillip A. Wilmarth, Larry L. David, Seung W. Cha, Sunghee Woo, Pavel Pevzner, Vineet Bafna, Gregory G. Burrows, Juha K. Rantala, Trevor Levin, Pavana Anur, Katie Johnson-Camacho, Shaadi Tabatabaei, Daniel J. Munson, Tullia C. Bruno, Jill E. Slansky, John W. Kappler, Naoto Hirano, Sebastian Boegel, Bernard A. Fox, Colt Egelston, Diana L. Simons, Grecia Jimenez, Peter P. Lee, Joe W. Gray & Paul T. Spellman. (2018) MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection. Journal of Proteomics 176, pages 13-23.
Crossref
Crossref
Gaochen Lan, Jie Li, Qiaomei Wen, Lin Lin, Libin Chen, Liyu Chen & Xi Chen. (2018) Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer. Oncology Letters.
Crossref
Crossref
Leisha A. Emens. (2018) Breast Cancer Immunotherapy: Facts and Hopes. Clinical Cancer Research 24:3, pages 511-520.
Crossref
Crossref
Amin RamezaniAbbas Ghaderi. (2018) Using a Dihydrofolate Reductase-Based Strategy for Producing the Biosimilar Version of Pertuzumab in CHO-S Cells. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 37:1, pages 26-37.
Crossref
Crossref
Elizabeth D Thompson, Janis M Taube, Rebecca J Asch-Kendrick, Aleksandra Ogurtsova, Haiying Xu, Rajni Sharma, Alan Meeker, Pedram Argani, Leisha A Emens & Ashley Cimino-Mathews. (2017) PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. Modern Pathology 30:11, pages 1551-1560.
Crossref
Crossref
Jianxin Hu, Junfeng Hu, Xiandong Liu, Chao Hu, Ming Li & Wei Han. (2017) Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer. Medicine 96:42, pages e8310.
Crossref
Crossref
Manuel Picon-Ruiz, Cynthia Morata-Tarifa, Janeiro J. Valle-Goffin, Eitan R. Friedman & Joyce M. Slingerland. (2017) Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA: A Cancer Journal for Clinicians 67:5, pages 378-397.
Crossref
Crossref
Muhammad Tariq, Jieqiong Zhang, Guikai Liang, Ling Ding, Qiaojun He & Bo Yang. (2017) Macrophage Polarization: Anti-Cancer Strategies to Target Tumor-Associated Macrophage in Breast Cancer. Journal of Cellular Biochemistry 118:9, pages 2484-2501.
Crossref
Crossref
Kenji Gonda, Masahiko Shibata, Tohru Ohtake, Yoshiko Matsumoto, Kazunoshin Tachibana, Noriko Abe, Hitoshi Ohto, Kenichi Sakurai & Seiichi Takenoshita. (2017) Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer. Oncology Letters 14:2, pages 1766-1774.
Crossref
Crossref
Robert H. Vonderheide, Susan M. Domchek & Amy S. Clark. (2017) Immunotherapy for Breast Cancer: What Are We Missing?. Clinical Cancer Research 23:11, pages 2640-2646.
Crossref
Crossref
Mariam Mansour, Zhi Ling Teo, Stephen J. Luen & Sherene Loi. (2017) Advancing Immunotherapy in Metastatic Breast Cancer. Current Treatment Options in Oncology 18:6.
Crossref
Crossref
Andrew M K Law, Elgene Lim, Christopher J Ormandy & David Gallego-Ortega. (2017) The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. Endocrine-Related Cancer 24:4, pages R123-R144.
Crossref
Crossref
Andrea Ravelli, Giandomenico Roviello, Daniele Cretella, Andrea Cavazzoni, Alessandra Biondi, Maria Rosa Cappelletti, Laura Zanotti, Giuseppina Ferrero, Marco Ungari, Fabrizio Zanconati, Alberto Bottini, Roberta Alfieri, Pier Giorgio Petronini & Daniele Generali. (2017) Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. Tumor Biology 39:4, pages 101042831769502.
Crossref
Crossref
Xi Chen, Qianqian Shao, Shengnan Hao, Zhonghua Zhao, Yang Wang, Xiaofan Guo, Ying He, Wenjuan Gao & Haiting Mao. (2017) CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function. Oncotarget 8:8, pages 13703-13715.
Crossref
Crossref
Lin-Yu Yu, Jie Tang, Cong-Min Zhang, Wen-Jing Zeng, Han Yan, Mu-Peng Li & Xiao-Ping Chen. (2017) New Immunotherapy Strategies in Breast Cancer. International Journal of Environmental Research and Public Health 14:1, pages 68.
Crossref
Crossref
Dominic Amara, Denise M. Wolf, Laura van ’t Veer, Laura Esserman, Michael Campbell & Christina Yau. (2016) Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer. Breast Cancer Research and Treatment 161:1, pages 41-50.
Crossref
Crossref
Alison Spellman & Shou-Ching Tang. (2016) Immunotherapy for breast cancer: past, present, and future. Cancer and Metastasis Reviews 35:4, pages 525-546.
Crossref
Crossref
Olivia C. IhediohaRobert P.C. ShiuJude E. UzonnaYvonne Myal. (2016) Prolactin-Inducible Protein: From Breast Cancer Biomarker to Immune Modulator—Novel Insights from Knockout Mice. DNA and Cell Biology 35:10, pages 537-541.
Crossref
Crossref
Cristina Migali, Monica Milano, Dario Trapani, Carmen Criscitiello, Angela Esposito, Marzia Locatelli, Ida Minchella & Giuseppe Curigliano. (2016) Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. Therapeutic Advances in Medical Oncology 8:5, pages 360-374.
Crossref
Crossref
B. Verret & D. Loirat. (2016) Immunothérapie et cancer du seinImmunotherapy and breast cancer. Oncologie 18:9-10, pages 551-558.
Crossref
Crossref
Yong Cheng & Jeffery S. Schorey. (2016) Targeting soluble proteins to exosomes using a ubiquitin tag. Biotechnology and Bioengineering 113:6, pages 1315-1324.
Crossref
Crossref
Marina B. Stenina, E. V Tsareva, A. A Zharov & S. A Tyulyandin. (2016) Tumor infiltrating lymphocytes: biological essence and clinical significance in breast cancer. Russian Journal of Oncology 21:1-2, pages 92-100.
Crossref
Crossref
Hirotake Abe, Haruka Wada, Muhammad Baghdadi, Sayaka Nakanishi, Yuu Usui, Takahiro Tsuchikawa, Toshiaki Shichinohe, Satoshi Hirano & Ken-ichiro Seino. (2016) Identification of a highly immunogenic mouse breast cancer sub cell line, 4T1-S. Human Cell 29:2, pages 58-66.
Crossref
Crossref
Elizabeth Thompson, Janis M Taube, Hillary Elwood, Rajni Sharma, Alan Meeker, Hind Nassar Warzecha, Pedram Argani, Ashley Cimino-Mathews & Leisha A Emens. (2016) The immune microenvironment of breast ductal carcinoma in situ. Modern Pathology 29:3, pages 249-258.
Crossref
Crossref
Malgorzata E. Wojtowicz, Barbara K. Dunn & Asad Umar. (2016) Immunologic approaches to cancer prevention—current status, challenges, and future perspectives. Seminars in Oncology 43:1, pages 161-172.
Crossref
Crossref
M. Schmalzing, M. Krockenberger, A. Honig & H.‑P. Tony. (2016) Gynäkologische Malignome bei Patientinnen mit rheumatisch‑entzündlichen SystemerkrankungenGynecological cancers in patients with inflammatory rheumatic diseases. Zeitschrift für Rheumatologie 75:1, pages 63-68.
Crossref
Crossref
Davide Bedognetti, Cristina Maccalli, Salha B.J. Al Bader, Francesco M. Marincola & Barbara Seliger. (2016) Checkpoint Inhibitors and Their Application in Breast Cancer. Breast Care 11:2, pages 108-115.
Crossref
Crossref
Sathana Dushyanthen, Paul A. Beavis, Peter Savas, Zhi Ling Teo, Chenhao Zhou, Mariam Mansour, Phillip K. Darcy & Sherene Loi. (2015) Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Medicine 13:1.
Crossref
Crossref
Chiara Dellepiane, Michela Lia & Mario Roberto Sertoli. (2015) CTLA-4 checkpoint blockade in breast cancer, a case in point report. Journal for ImmunoTherapy of Cancer 3:S1.
Crossref
Crossref
Sibylle Loibl & Jenny Furlanetto. (2015) Targeting the Immune System in Breast Cancer: Hype or Hope?: TILs and Newer Immune-Based Therapies Being Evaluated for HER2+ and TNBC. Current Breast Cancer Reports 7:4, pages 203-209.
Crossref
Crossref
Philipp MüllerMatthias KreuzalerTarik KhanDaniela S. ThommenKea MartinKatharina GlatzSpasenija SavicNadia HarbeckUlrike NitzOleg GluzMichael von Bergwelt-BaildonHans KreipeSai ReddyMatthias ChristgenAlfred Zippelius. (2015)
Trastuzumab emtansine (T-DM1) renders HER2
+
breast cancer highly susceptible to CTLA-4/PD-1 blockade
. Science Translational Medicine 7:315.
Crossref
Crossref
Gabriele Multhoff, Alan G. Pockley, Thomas E. Schmid & Daniela Schilling. (2015) The role of heat shock protein 70 (Hsp70) in radiation-induced immunomodulation. Cancer Letters 368:2, pages 179-184.
Crossref
Crossref
Evan J. Lipson, Patrick M. Forde, Hans-Joerg Hammers, Leisha A. Emens, Janis M. Taube & Suzanne L. Topalian. (2015) Antagonists of PD-1 and PD-L1 in Cancer Treatment. Seminars in Oncology 42:4, pages 587-600.
Crossref
Crossref
Haiming Yu, Junlan Yang, Shunchang Jiao, Ying Li, Wei Zhang & Jiandong Wang. (2015) Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis. Cancer Immunology, Immunotherapy 64:7, pages 853-860.
Crossref
Crossref
Galit Alter & Rafick Pierre Sekaly. (2015) Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity. Vaccine 33, pages B55-B59.
Crossref
Crossref
Cynthia X. Ma, Tomás Reinert, Izabela Chmielewska & Matthew J. Ellis. (2015) Mechanisms of aromatase inhibitor resistance. Nature Reviews Cancer 15:5, pages 261-275.
Crossref
Crossref
Sathana Dushyanthen, Peter Savas, Karen Willard-Gallo, Carsten Denkert, Roberto Salgado & Sherene Loi. (2015) Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker?. Current Breast Cancer Reports 7:1, pages 59-70.
Crossref
Crossref
Brenda Ernst & Karen S. Anderson. (2015) Immunotherapy for the Treatment of Breast Cancer. Current Oncology Reports 17:2.
Crossref
Crossref
Gang Chen, Richa Gupta, Silvia Petrik, Marina Laiko, James M. Leatherman, Justin M. Asquith, Maithili M. Daphtary, Elizabeth Garrett-Mayer, Nancy E. Davidson, Kellie Hirt, Maureen Berg, Jennifer N. Uram, Tianna Dauses, John Fetting, Elizabeth M. Duus, Saadet Atay-Rosenthal, Xiaobu Ye, Antonio C. Wolff, Vered Stearns, Elizabeth M. Jaffee & Leisha A. Emens. (2014) A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF–Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer. Cancer Immunology Research 2:10, pages 949-961.
Crossref
Crossref
Jaime Fornetti, Holly A. Martinson, Courtney B. Betts, Traci R. Lyons, Sonali Jindal, Qiuchen Guo, Lisa M. Coussens, Virginia F. Borges & Pepper Schedin. (2014) Mammary Gland Involution as an Immunotherapeutic Target for Postpartum Breast Cancer. Journal of Mammary Gland Biology and Neoplasia 19:2, pages 213-228.
Crossref
Crossref
Carlos M. Galmarini, Olivier Tredan & Felipe C. Galmarini. (2013) Concomitant resistance and early-breast cancer: should we change treatment strategies?. Cancer and Metastasis Reviews 33:1, pages 271-283.
Crossref
Crossref
David B PageJarushka Naidoo & Heather L McArthur. (2014) Emerging immunotherapy strategies in breast cancer. Immunotherapy 6:2, pages 195-209.
Crossref
Crossref
Xinguo Jiang. (2014) Harnessing the immune system for the treatment of breast cancer. Journal of Zhejiang University SCIENCE B 15:1, pages 1-15.
Crossref
Crossref
Yongqun He, Zhiwei Cao, Anne S De Groot, Vladimir Brusic, Christian Schönbach & Nikolai Petrovsky. (2013) Computational vaccinology and the ICoVax 2012 workshop. BMC Bioinformatics 14:S4.
Crossref
Crossref